Navigation Links
DTX 800 Multimode Detector

ProductsDTX 800 Multimode Detector
Company Beckman Coulter, Inc.
Item DTX 800 Multimode Detector
Features Inquire
Description The DTX Series Multimode Detectors provide unmatched value and flexibility for a variety of application and automation needs. Capable of performing fluorescence, luminescence and absorbance measurements on the same instrument, the DTX Series can operate as standalone instruments or can be integrated seamlessly with Beckman Coulters Biomek Laboratory Automation Workstations. The DTX Series is ideal for a broad range of Systems Biology applications, including drug discovery, genomics, proteomics and cell-based research. The unique optics design (patents pending) ensures precise performance and sensitivity across all detection modes. The instruments facilitate easy integration with automated liquid handling systems via a choice of plate loading options. These include an extra-wide plate access door, and the ability to accept plates in portrait or landscape formats. In addition, the detectors intuitive software platform provides instrument control and easy protocol development, as well as compatibility with Beckman Coulters Biomek software program.

The DTX 800 features fluorescence intensity (top reading), absorbance (visible) and glow luminescence for 96- to 384-well plates, as well as linear and orbital shaking. Users can program endpoint, kinetic, multiple wavelength, linear scan and area scan measurement types. Easily accessible six-position filter slides enable wavelength selection from 340nm to 650nm.

Info Beckman Coulter, Inc.
Customer Service: (800) 742-2345
Web site: http://www.beckmancoulter.com

Related medicine products :

1. Multimode reader
2. DTX 880 Multimode Detector
3. SA-1000 Air Detector/Clamp
4. H-30 Air Detector Clamp
With the touch of a button, the Marco Encore Automatic Chair quickly reclines from an upright position to a fully horizontal, flat-table mode-or anywhere in between.
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Medicine Products:
(Date:12/3/2008)...cinated by their brains, the way they work, change...ation for the Advancement of Science (AAAS) recomm...t fascination to engage middle and high school stu...hey shouldn,t drink alcohol. , "Parents need ever...o drink alcohol, particularly during the holiday s...
(Date:12/3/2008)...Dec. 3 Medical device manufacturer...y with the new requirements of the,amended Europe... in March,2010, a newly released Nerac white pape...easing share in the growing $86 billion,market th....S. medical device,companies, profits," write Ner...
(Date:12/3/2008)...o new treatments for PTSD, researchers say , ...e with stress-related psychiatric conditions have ...ps govern memories, a new study suggests. , For...airs to two groups of patients, those with major d...rs, and a healthy control group. , The researc...
(Date:12/3/2008).... Results of a phase III, international randomize...e for treating advanced ovarian cancer that signif...aths compared to the previously established treatm...nial Meeting of the International Gynecologic Canc...or impact on many countries where the new standard...
Breaking Medicine News(10 mins):Health News:When 'just say no' isn't enough: Try science 2Health News:New Requirements of EU Medical Device Directive Need Immediate Action, Nerac Analysts Urge in Newly Published White Paper 2Health News:New Requirements of EU Medical Device Directive Need Immediate Action, Nerac Analysts Urge in Newly Published White Paper 3Health News:Memory Formation Different in Those With Stress-Related Psychiatric Disorders 2Health News:International study supports new standard of treatment for women with advanced ovarian cancer 2
...rom Norway looked at 4.7 lakh births between 1977 ...ased blood pressure which is dangerous to the baby...n born in August had the lowest risk of pre-eclamp...e National Institute of Public Health in Oslo say ...
...have stated that Men who suffer from constipation ...ive brain disease Parkinson's some have suggested ...ction of the gut long before it manifests itself e...e research, said: "It could help us more effective...
... the FDA issued a statement about the potential fo...drug, Accutane. And now, reports say that the 15-y...per was prescribed the drug. At this point, invest...les J. Bishop, was actually taking Accutane at the...
...tudy has found gardening is the best form of exerc... Dr Sara Fenn and colleagues at the University of ...,000 women, including more than 3,000 aged 50 year...gardened at least once a week showed higher bone d...
Other Medicine News:
(Date:12/3/2008)...IEGO, Dec. 3 Vical Incor...usive, binding letter of intent with EIP,Eczaciba...ng of the company,s,Allovectin-7(R) immunotherape...Republic of Northern Cyprus. EIP has agreed to obt...rritory and to pay Vical upfront and milestone pay...
(Date:12/2/2008)...GO, Dec. 3 Breast-speci...ction of cancers not found on mammograms or by,cl...at the annual meeting of,the Radiological Society...ify the most difficult to detect breast cancer-inv... F. Brem, M.D., professor of,radiology and direct...
(Date:12/2/2008)...A, Kan., Dec. 2 IBT Laboratories, ...earch laboratory specializing in immunology and al...tests to evaluate the response of patients whose ... immunodeficiency disorder, chemotherapy drugs, or...to prevent rejection of a transplant. The company ...
(Date:12/2/2008)...E, Ill., Dec. 2 Horizon Therapeuti...any, today announced that two pivotal,Phase 3 tri...ndidate, HZT-501,met all primary endpoints. HZT-...product containing ibuprofen and famotidine, demon...the incidence of non-steroidal,anti-inflammatory ...
Breaking Medicine Technology:Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Plastic Surgeon Joins Established Practice 13056 1Plastic Surgeon Joins Established Practice 13056 24th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 14th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 24th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 34th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 4BioInformatics LLC Studies Trade Show Exhibition Strategies in the Life Science Market 3600 1BioInformatics LLC Studies Trade Show Exhibition Strategies in the Life Science Market 3600 2BioInformatics LLC Studies Trade Show Exhibition Strategies in the Life Science Market 3600 3Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 1Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 2Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 3
... in Blood Glucose,Control and Progressive Weight L...l/ -- Amylin,Pharmaceuticals, Inc. and Eli Lilly a...at showed BYETTA(R) (exenatide) injection,sustaine...ve weight,loss through three and a half years of t...improvements in cardiovascular risk,factors in peo...
... 25, 2007--Gilead,Sciences, Inc. (Nasdaq:GILD) tod...trial evaluating the company,s once-daily,anti-HIV...tenofovir,DF) 300 mg as a potential treatment for ... primary efficacy endpoint. The data show,that Vir...tiviral,drug Hepsera(R) (adefovir dipivoxil) among...
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6